Surmodics (Surmodics) Cash And Cash Equivalents : $23.4 Mil (As of Dec. 2023)

View and export this data going back to 1998. Start your Free Trial

What is Surmodics Cash And Cash Equivalents?

Surmodics's quarterly cash and cash equivalents declined from Jun. 2023 ($44.58 Mil) to Sep. 2023 ($41.42 Mil) but then stayed the same from Sep. 2023 ($41.42 Mil) to Dec. 2023 ($23.36 Mil).

Surmodics's annual cash and cash equivalents declined from Sep. 2021 ($31.15 Mil) to Sep. 2022 ($19.00 Mil) but then increased from Sep. 2022 ($19.00 Mil) to Sep. 2023 ($41.42 Mil).

Surmodics Cash And Cash Equivalents Historical Data

The historical data trend for Surmodics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surmodics Cash And Cash Equivalents Chart

Surmodics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Cash And Cash Equivalents

Get a 7-Day Free Trial

30.36

30.79

31.15

19.00

41.42

Surmodics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															26.43	19.18	44.58	41.42	23.36

Surmodics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Surmodics (NAS:SRDX) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Surmodics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Surmodics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Surmodics (Surmodics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Surmodics Inc (NAS:SRDX) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

SU6:Germany

Address

9924 West 74th Street, Eden Prairie, MN, USA, 55344

Website

https://www.surmodics.com

Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.

Executives

Jose H Bedoya	director
David Dantzker	other: See Explanation of Responses	80 CUTTERMILL ROAD STE 311, GREAT NECK NY 11021
Kalich Ronald B Sr	director
Gary R Maharaj	director, officer: President & CEO	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Joseph J. Stich	officer: VP, Corp Dev & Strat Planning	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Charles W Olson	officer: General Manager
John D. Manders	officer: Corporate Controller	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Gordon S. Weber	officer: Sr. VP of Legal, GC and Sec.	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Nusrath Sultana	officer: VP, Clinical Affairs	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Lisa Wipperman Heine	director	1244 76TH STREET WEST, INVER GROVE HEIGHTS MN 55077
Teri Woodwick Sides	officer: Senior VP and CMO	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Gregg S Sutton	officer: VP of Research and Development	6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Susan E Knight	director	9154 BRECKENRIDGE LANE, EDEN PRAIRIE MN 55437
Bryan K Phillips	officer: Dep. Gen. Counsel & Corp. Sec.	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Timothy J. Arens	officer: General Manager - IVD	9924 WEST 74TH STREET, EDEN PRAIRIE X1 55344